Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 2/20 | 0.72 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108087 | 0.91 | TAAR1 (0.77) | CALM1TAAR1SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL29694229 | 0.88 | TAAR1 (0.79) | CALM1TAAR1HDAC1HDAC3HDAC2 | |
| SCHEMBL79785 | 0.88 | CALM1 (0.64) | CALM1TAAR1HDAC1HDAC3HDAC2 | |
| SCHEMBL9214607 | 0.88 | TAAR1 (0.62) | CALM1TAAR1HDAC1HDAC3HDAC2 | |
| SCHEMBL95457 | 0.88 | TAAR1 (0.62) | CALM1TAAR1HDAC1HDAC3HDAC2 | |
| SCHEMBL29604675 | 0.88 | TAAR1 (0.62) | CALM1TAAR1HDAC1HDAC3HDAC2 | |
| SCHEMBL7357999 | 0.88 | TAAR1 (0.62) | CALM1TAAR1HDAC1HDAC3HDAC2 | |
| SCHEMBL1813526 | 0.88 | TAAR1 (0.79) | CALM1TAAR1HDAC1HDAC3HDAC2 | |
| SCHEMBL4055725 | 0.88 | TAAR1 (0.62) | CALM1TAAR1HDAC1HDAC3HDAC2 | |
| SCHEMBL79307 | 0.88 | TAAR1 (0.62) | CALM1TAAR1HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630135-A1 | PIPERONYL BUTOXIDE DISTILLATION PROCESS WITH RECTIFICATION FOR OBTAINING HIGH PURITY PBO | ENDURA S.p.A. (IT) | 2025-10-15 | — | — | EP | claimed |
| WO-2024121591-A1 | DISTILLATION OF PIPERONYL BUTOXIDE | ENDURA S.P.A. (IT) | 2024-06-13 | — | — | WO | claimed |
| WO-2024120993-A1 | PIPERONYL BUTOXIDE DISTILLATION PROCESS WITH RECTIFICATION FOR OBTAINING HIGH PURITY PBO | ENDURA S.P.A. (IT) | 2024-06-13 | — | — | WO | claimed |
| EP-4630135-A1 | PIPERONYL BUTOXIDE DISTILLATION PROCESS WITH RECTIFICATION FOR OBTAINING HIGH PURITY PBO | ENDURA S.p.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| EP-4630135-A1 | PIPERONYL BUTOXIDE DISTILLATION PROCESS WITH RECTIFICATION FOR OBTAINING HIGH PURITY PBO | ENDURA S.p.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121591-A1 | DISTILLATION OF PIPERONYL BUTOXIDE | ENDURA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121591-A1 | DISTILLATION OF PIPERONYL BUTOXIDE | ENDURA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024120993-A1 | PIPERONYL BUTOXIDE DISTILLATION PROCESS WITH RECTIFICATION FOR OBTAINING HIGH PURITY PBO | ENDURA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024120993-A1 | PIPERONYL BUTOXIDE DISTILLATION PROCESS WITH RECTIFICATION FOR OBTAINING HIGH PURITY PBO | ENDURA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009017848-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES SUCH AS SYSTEMIC AA AMYLOIDOSIS | PROTEO TECH INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008154083-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | PROTEO TECH INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008097692-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | PROTEOTECH INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | disclosed |
| WO-2003101927-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTEOTECH, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | IAPP, SNCA, APP | CALM1 2272/4885TAAR1 1303/4885HDAC1 4771/4885 |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | SNCA, PARK7, COMT | CALM1 1900/4885TAAR1 2937/4885HDAC1 3065/4885 |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | IAPP, APP, SNCA | CALM1 1802/4885TAAR1 2362/4885HDAC1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.